Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

INTRODUCTION: Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)(1–40) and Aβ(1–42) in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This...

詳細記述

保存先:
書誌詳細
出版年:Alzheimers Dement (N Y)
主要な著者: Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2018
主題:
Featured Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258891/
https://ncbi.nlm.nih.gov/pubmed/30511011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.10.001
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料